218 related articles for article (PubMed ID: 35790401)
1. Cannabinoid 1 and mu-Opioid Receptor Agonists Synergistically Inhibit Abdominal Pain and Lack Side Effects in Mice.
Yu Y; Tsang QK; Jaramillo-Polanco J; Lomax AE; Vanner SJ; Reed DE
J Neurosci; 2022 Aug; 42(33):6313-6324. PubMed ID: 35790401
[TBL] [Abstract][Full Text] [Related]
2. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.
Datta U; Kelley LK; Middleton JW; Gilpin NW
Psychopharmacology (Berl); 2020 Dec; 237(12):3729-3739. PubMed ID: 32857187
[TBL] [Abstract][Full Text] [Related]
3. The cannabinoid CB
Iyer V; Slivicki RA; Thomaz AC; Crystal JD; Mackie K; Hohmann AG
Eur J Pharmacol; 2020 Nov; 886():173544. PubMed ID: 32896549
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
5. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
6. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain.
Yuill MB; Hale DE; Guindon J; Morgan DJ
Mol Pain; 2017; 13():1744806917728227. PubMed ID: 28879802
[TBL] [Abstract][Full Text] [Related]
7. Opioid-Induced Pronociceptive Signaling in the Gastrointestinal Tract Is Mediated by Delta-Opioid Receptor Signaling.
Jaramillo-Polanco J; Lopez-Lopez C; Yu Y; Neary E; Hegron A; Canals M; Bunnett NW; Reed DE; Lomax AE; Vanner SJ
J Neurosci; 2022 Apr; 42(16):3316-3328. PubMed ID: 35256532
[TBL] [Abstract][Full Text] [Related]
8. OCP002, a Mixed Agonist of Opioid and Cannabinoid Receptors, Produces Potent Antinociception With Minimized Side Effects.
Xu B; Zhang Q; Chen D; Zhang M; Zhang R; Zhao W; Qiu Y; Xu K; Xiao J; Niu J; Shi Y; Li N; Fang Q
Anesth Analg; 2023 Feb; 136(2):373-386. PubMed ID: 36638515
[TBL] [Abstract][Full Text] [Related]
9. Histone methyltransferase G9a diminishes expression of cannabinoid CB
Luo Y; Zhang J; Chen L; Chen SR; Chen H; Zhang G; Pan HL
J Biol Chem; 2020 Mar; 295(11):3553-3562. PubMed ID: 32024693
[TBL] [Abstract][Full Text] [Related]
10. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
[TBL] [Abstract][Full Text] [Related]
11. The antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioids.
Negrete R; Hervera A; Leánez S; Martín-Campos JM; Pol O
PLoS One; 2011; 6(10):e26688. PubMed ID: 22031841
[TBL] [Abstract][Full Text] [Related]
12. Role of primary sensory neurone cannabinoid type-1 receptors in pain and the analgesic effects of the peripherally acting agonist CB-13 in mice.
Ford NC; Barpujari A; He SQ; Huang Q; Zhang C; Dong X; Guan Y; Raja SN
Br J Anaesth; 2022 Jan; 128(1):159-173. PubMed ID: 34844727
[TBL] [Abstract][Full Text] [Related]
13. Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists.
Maguire DR; France CP
J Pharmacol Exp Ther; 2014 Nov; 351(2):383-9. PubMed ID: 25194020
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression.
Wiese BM; Liktor-Busa E; Levine A; Couture SA; Nikas SP; Ji L; Liu Y; Mackie K; Makriyannis A; Largent-Milnes TM; Vanderah TW
Cannabis Cannabinoid Res; 2021 Oct; 6(5):401-412. PubMed ID: 33998869
[No Abstract] [Full Text] [Related]
15. Low Basal CB2R in Dopamine Neurons and Microglia Influences Cannabinoid Tetrad Effects.
Liu QR; Canseco-Alba A; Liang Y; Ishiguro H; Onaivi ES
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371336
[TBL] [Abstract][Full Text] [Related]
16. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain.
Yu XH; Cao CQ; Martino G; Puma C; Morinville A; St-Onge S; Lessard É; Perkins MN; Laird JMA
Pain; 2010 Nov; 151(2):337-344. PubMed ID: 20696525
[TBL] [Abstract][Full Text] [Related]
17. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.
Grenald SA; Young MA; Wang Y; Ossipov MH; Ibrahim MM; Largent-Milnes TM; Vanderah TW
Neuropharmacology; 2017 Apr; 116():59-70. PubMed ID: 28007501
[TBL] [Abstract][Full Text] [Related]
18. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
Tham SM; Angus JA; Tudor EM; Wright CE
Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
20. Effects of opioid/cannabinoid mixtures on impulsivity and memory in rhesus monkeys.
Minervini V; France CP
Behav Pharmacol; 2020 Apr; 31(2&3):233-248. PubMed ID: 32101988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
